Jacc: Cardiooncology最新文献

{"title":"Full Issue PDF","authors":"","doi":"10.1016/S2666-0873(24)00315-6","DOIUrl":"10.1016/S2666-0873(24)00315-6","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages I-CLXXXVII"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142438321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Survivors and Cardiovascular Risk: What Patients Should Know From the Perspective of Another Survivor","authors":"Steven Petrow","doi":"10.1016/j.jaccao.2024.08.002","DOIUrl":"10.1016/j.jaccao.2024.08.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 808-810"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes","authors":"Darryl P. Leong MBBS, MPH, MBiostat, PhD ,&nbsp;Vincent Fradet MD, PhD ,&nbsp;Tamim Niazi MD ,&nbsp;Joseph B. Selvanayagam MBBS, DPhil ,&nbsp;Robert Sabbagh MD, MSc ,&nbsp;Celestia S. Higano MD ,&nbsp;Steven Agapay BSc ,&nbsp;Sumathy Rangarajan MSc ,&nbsp;Rajibul Mian PhD ,&nbsp;Carlos A.K. Nakashima MD, PhD ,&nbsp;Negareh Mousavi MD ,&nbsp;Ian Brown MD ,&nbsp;Felipe H. Valle MD, PhD ,&nbsp;Luke T. Lavallée MDCM, MSc ,&nbsp;Bobby Shayegan MD ,&nbsp;Kelvin K.H. Ng MBBS ,&nbsp;Darin D. Gopaul MD ,&nbsp;Germano D. Cavalli MD ,&nbsp;Sonia Saavedra MD ,&nbsp;Jose P. Lopez-Lopez MD ,&nbsp;Jehonathan Pinthus MD, PhD","doi":"10.1016/j.jaccao.2024.07.011","DOIUrl":"10.1016/j.jaccao.2024.07.011","url":null,"abstract":"<div><h3>Background</h3><div>There are limited data on the physical effects of androgen deprivation therapy (ADT) for prostate cancer (PC), and on the relationships of such measures of adiposity and strength to cardiovascular outcomes.</div></div><div><h3>Objectives</h3><div>The primary objective of this study was to evaluate the relationships of measures of adiposity and strength to cardiovascular outcomes (cardiovascular death, myocardial infarction, stroke, heart failure, arterial revascularization, peripheral arterial disease, and venous thromboembolism) in patients with PC. A secondary objective was to characterize the relationships between ADT use and 12-month changes in these physical measures.</div></div><div><h3>Methods</h3><div>This international, prospective cohort study included 3,967 patients with PC diagnosed in the prior 12 months or being treated with ADT for the first time. Median follow-up duration was 2.3 years.</div></div><div><h3>Results</h3><div>Participants’ mean age was 68.5 years, and 1,731 (43.6%) were exposed to ADT. ADT was associated with a 1.6% increase in weight, a 2.2% increase in waist circumference, a 1.6% increase in hip circumference, a 0.1% increase in waist-to-hip ratio, a 27.4% reduction in handgrip strength, and a 0.1% decrease in gait speed. High waist circumference and low handgrip strength were associated with adverse cardiovascular outcomes. Adjusting for age, education, race, tobacco and alcohol use, physical activity, cardiovascular disease, glomerular filtration rate, and ADT use, waist circumference above the highest quartile (110 cm) and handgrip strength below the lowest quartile (29.5 kg) were associated with higher likelihoods of a future cardiovascular event, with respective HRs of 1.40 (95% CI: 1.03-1.90; <em>P</em> = 0.029) and 1.59 (95% CI: 1.14-2.22; <em>P</em> = 0.006).</div></div><div><h3>Conclusions</h3><div>ADT was associated with increased adiposity and reduced strength over 12-month follow-up. High waist circumference and low baseline strength were associated with future adverse cardiovascular outcomes.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 761-771"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142438298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carvedilol to Improve Cardiac Remodeling in Anthracycline-Exposed Childhood Cancer Survivors","authors":"Saro H. Armenian DO, MPH ,&nbsp;Melissa M. Hudson MD ,&nbsp;Lanie Lindenfeld MA ,&nbsp;Sitong Chen MS ,&nbsp;Eric J. Chow MD, MPH ,&nbsp;Steven Colan MD ,&nbsp;Meagan Echevarria MPH ,&nbsp;F. Lennie Wong PhD ,&nbsp;Ming Hui Chen MD ,&nbsp;Smita Bhatia MD, MPH","doi":"10.1016/j.jaccao.2024.07.015","DOIUrl":"10.1016/j.jaccao.2024.07.015","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 791-793"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142438302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Considerations Before Cancer Therapy","authors":"Zahra Raisi-Estabragh MBChB, PhD ,&nbsp;Alexandra C. Murphy MBBS, PhD ,&nbsp;Sivatharshini Ramalingam MBBS ,&nbsp;Marielle Scherrer-Crosbie MD, PhD ,&nbsp;Teresa Lopez-Fernandez MD ,&nbsp;Kerry L. Reynolds MD ,&nbsp;Marianne Aznar PhD ,&nbsp;Amy E. Lin MD, PhD ,&nbsp;Peter Libby MD ,&nbsp;Raul Cordoba MD, PhD ,&nbsp;Christine Bredsen-Masley MD, PhD ,&nbsp;Ashu Wechalekar MBBS, MD ,&nbsp;Jane Apperley MBBS, MD ,&nbsp;Richard K. Cheng MD, MSc ,&nbsp;Charlotte H. Manisty MBBS, PhD","doi":"10.1016/j.jaccao.2024.07.017","DOIUrl":"10.1016/j.jaccao.2024.07.017","url":null,"abstract":"<div><div>Baseline cardiovascular assessment before the initiation of potentially cardiotoxic cancer therapies is a key component of cardio-oncology, aiming to reduce cardiovascular complications and morbidity in patients and survivors. Recent clinical practice guidelines provide both general and cancer therapy–specific recommendations for baseline cardiovascular toxicity risk assessment and management, including the use of dedicated risk scores, cardiovascular imaging, and biomarker testing. However, the value of such interventions in altering disease trajectories has not been established, with many recommendations based on expert opinion or Level of Evidence: C, studies with a potential for high risk of bias. Advances in understanding underlying mechanisms of cardiotoxicity and the increased availability of genetic and immunologic profiling present new opportunities for personalized risk assessment. This paper evaluates the existing evidence on cardiovascular care of cancer patients before cardiotoxic cancer therapy and highlights gaps in evidence and priorities for future research.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 631-654"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction","authors":"Hyukjin Park MD ,&nbsp;Nuri Lee MD ,&nbsp;Cho Hee Hwang MPH ,&nbsp;Sang-Geon Cho MD ,&nbsp;Ga Hui Choi MD ,&nbsp;Jae Yeong Cho MD ,&nbsp;Hyun Ju Yoon MD ,&nbsp;Kye Hun Kim MD ,&nbsp;Youngkeun Ahn MD","doi":"10.1016/j.jaccao.2024.07.018","DOIUrl":"10.1016/j.jaccao.2024.07.018","url":null,"abstract":"<div><h3>Background</h3><div>The long-term prognosis after the discontinuation of cardioprotective therapy (CPT) in patients with cancer therapeutics–related cardiac dysfunction (CTRCD) that has shown improvement remains unclear.</div></div><div><h3>Objectives</h3><div>This study aims to assess the prognosis after CPT withdrawal in patients exhibiting improved CTRCD.</div></div><div><h3>Methods</h3><div>In this retrospective analysis of a single-center prospective cohort study, patients with improved CTRCD, defined as an increase in left ventricular ejection fraction (LVEF) ≥10 percentage points from the time of CTRCD diagnosis, were included. We analyzed their clinical outcomes, which included hospitalization for heart failure or a decrease in LVEF ≥10 percentage points within 2 years after CTRCD improvement, alongside echocardiographic changes.</div></div><div><h3>Results</h3><div>The cohort comprised 134 patients with improved CTRCD. The median follow-up duration after CTRCD diagnosis was 368.3 days (Q1-Q3: 160-536 days). After improvement, 90 patients continued CPT (continued group [CG]) and 44 withdrew CPT (withdrawn group [WG]). Among patients whose baseline LVEF at CTRCD diagnosis ranged from 45% to 55%, the final mean LVEF was comparable between both groups (CG: 64.9% ± 4.4% vs WG: 62.9% ± 4.2%; <em>P</em> = 0.059). However, for patients with a baseline LVEF &lt;45%, the final mean LVEF was significantly lower in the WG (CG: 53.3% ± 6.4% vs WG: 48.2% ± 6.9%; <em>P</em> &lt; 0.001). The occurrence of composite major clinical events was notably higher in the WG (HR: 3.06; 95% CI: 1.51-7.73; <em>P</em> = 0.002).</div></div><div><h3>Conclusions</h3><div>Patients who withdrew CPT after demonstrating improvement in CTRCD experienced worse clinical outcomes. Notably, a significant decrease in LVEF was observed after CPT withdrawal in patients with a baseline LVEF &lt;45%.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 699-710"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Priorities in Cardio-Oncology","authors":"Bonnie Ky MD, MSCE, FACC","doi":"10.1016/j.jaccao.2024.09.002","DOIUrl":"10.1016/j.jaccao.2024.09.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Page 811"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142438319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guiding Treatment With Recovered CTRCD","authors":"Brian P. Halliday MBChB, PhD ,&nbsp;Muhummad Sohaib Nazir MBBS, PhD","doi":"10.1016/j.jaccao.2024.09.003","DOIUrl":"10.1016/j.jaccao.2024.09.003","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 711-713"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142438322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenomics of Cardio-Oncology","authors":"Brian T. Joyce PhD","doi":"10.1016/j.jaccao.2024.07.013","DOIUrl":"10.1016/j.jaccao.2024.07.013","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 743-745"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology","authors":"Kyle D. Shead MRes,&nbsp;Eline Huethorst PhD,&nbsp;Francis Burton PhD,&nbsp;Ninian N. Lang MBChB, PhD,&nbsp;Rachel C. Myles MBChB, PhD,&nbsp;Godfrey L. Smith PhD","doi":"10.1016/j.jaccao.2024.07.012","DOIUrl":"10.1016/j.jaccao.2024.07.012","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 678-683"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}